ArticleRSC advances2025
Doxorubicin drug delivery using an electrospun nanofiber membrane of chitosan-polycaprolactone with metal-organic framework: Box-Behnken optimization, anticancer treatment, and antimicrobial activity.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Electrospun nanofiber membrane of chitosan/polyvinyl alcohol embedded with DOX-loaded V-MOFs for controlled drug release and multifunctional biological activity.RSC advances · 2026Article
- Efficient removal of the ciprofloxacin drug using an electrospun Co/Al-layered double hydroxide-embedded chitosan/polyvinylidene fluoride nanofiber membrane.RSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic frameworks (MOFs) have become significant nanocarriers for drug delivery owing to their remarkable high surface area, adjustable porosity, and functional adaptability. This research focused on developing a multifunctional pH-responsive delivery system by encapsulating doxorubicin (DOX) within a lanthanum-based MOF (La-MOF) and integrating this complex into a biocompatible electrospun nanofiber membrane made of polycaprolactone (PCL) and chitosan (CS). The resulting DOX@La-MOF/CS-PCL nanofiber membrane was created by means of a one-step electrospinning technique and extensively analyzed using XRD, FTIR, XPS, SEM, EDX, and BET techniques to confirm its structural honesty, surface morphology, and chemical makeup. Drug release experiments indicated a dual-responsive behavior, demonstrating much higher DOX release at body temperature (37 °C) and in acidic environment (pH 5.0) that mimic the tumor micro environment. According to kinetic analysis, diffusion and erosion worked together to affect the release mechanism, which is consistent with zero-order, first-order, Korsmeyer-Peppas, as well as Higuchi models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.